	US 12,252,522 B2
	Myokines for treating cell proliferative and metabolic diseases and disorders
Hemant K. Roy, Chestnut Hill, MA (US); and Vadim Backman, Chicago, IL (US)
Assigned to Northwestern University, Evanston, IL (US)
Filed by Northwestern University, Evanston, IL (US)
Filed on Jan. 6, 2023, as Appl. No. 18/151,166.
Application 18/151,166 is a division of application No. 16/877,275, filed on May 18, 2020, granted, now 11,560,414.
Claims priority of provisional application 62/850,526, filed on May 20, 2019.
Claims priority of provisional application 62/848,914, filed on May 16, 2019.
Prior Publication US 2023/0340047 A1, Oct. 26, 2023
Int. Cl. A61K 38/18 (2006.01); A61K 31/282 (2006.01); A61K 38/00 (2006.01); A61K 38/19 (2006.01); A61P 3/10 (2006.01); A61P 9/00 (2006.01); A61P 35/00 (2006.01); C07K 14/47 (2006.01); C07K 14/475 (2006.01); C07K 14/52 (2006.01)

CPC C07K 14/475 (2013.01) [A61K 31/282 (2013.01); C07K 14/4703 (2013.01); A61K 38/00 (2013.01)]

6 Claims

1. A method for treating colorectal cancer in a subject in need thereof, the method comprising administering to the subject:

(a) an isolated fraction of myokines or a pharmaceutical formulation thereof, wherein the isolated fraction of myokines comprises an effective amount of one or more myokines, and wherein (i) the one or more myokines have a molecular weight greater than about 10 kDa; and/or (ii) the one or more myokines comprise myostatin, metrnl, or both of myostatin and metrnl; and

(b) an effective amount of a platinum-based chemotherapeutic drug or a pharmaceutical formulation thereof.